{"id":10067,"date":"2022-11-03T01:10:28","date_gmt":"2022-11-03T01:10:28","guid":{"rendered":"https:\/\/ultimatehealthreport.com\/why-go-to-a-cannabis-science-conference\/"},"modified":"2022-11-03T01:10:28","modified_gmt":"2022-11-03T01:10:28","slug":"why-go-to-a-cannabis-science-conference","status":"publish","type":"post","link":"https:\/\/ultimatehealthreport.com\/why-go-to-a-cannabis-science-conference\/","title":{"rendered":"Why Go to a Cannabis Science Conference?"},"content":{"rendered":"


\n<\/p>\n

\n

It was a sight to behold, as Dr. Franjo Grotenhermen, director of the International Association for Cannabinoid Medicines (IACM<\/span>), rolled in on a gurney, his large frame laying sideways with a microphone placed near his mouth. Unable to sit up or stand because of a rare, chronic disease, this German force of nature had arrived to give out the awards at the 12th IACM<\/span> conference in Basel, Switzerland, in October 2022.<\/p>\n

Several hundred people were in attendance when Grotenhermen presented the first award for the best clinical poster, an observational study on the use of a standardized cannabis oil extract with a THC<\/span>:CBD<\/span> ratio of 1:2 for severely demented patients. Of the 19 patients who participated in this 13-month study, none saw serious adverse events or discontinued use because of side effects. But there were noteworthy clinical improvements for rigidity, agitation, behavioral problems, decreased prescription drug use, and easier caregiving. Family members interviewed for the study expressed appreciation for the increased connection with a loved one who had been slipping away.<\/p>\n

(A complete list of the 43 posters that presented new findings at this year\u2019s IACM<\/span> can be seen here.)<\/p>\n

The Doctor<\/h2>\n
<\/p>\n

Dr. Franjo Grotenhermen and Dr. Rudolf Brenneisen<\/p>\n<\/div>\n

A major figure behind medical cannabis in Europe, Dr. Grotenhermen founded the IACM<\/span> with his American colleague Dr. Ethan Russo 22 years ago. A recent documentary film, \u2018The Doctor\u2019, describes how a friend from his political days at the university introduced Grotenhermen to the cannabis issue because he needed a report for the government on whether or not hemp can get you high. This research initially drew Grotenhermen into the history of cannabis as a medicine, and then he started learning more from his patients.<\/p>\n

\u201cHe\u2019s one who says and really, really thinks that the patient comes first,\u201d says Carola P\u00e9rez, the Spanish leader of the IACM<\/span> Patient Council.<\/p>\n

In 2017, Grotenhermen went on a hunger strike to protest restrictions in Germany\u2019s first medical cannabis laws. Lately, he\u2019s been pressuring the Bundestag, Germany\u2019s Parliament, to force insurance companies to follow the law and only refuse to cover medical cannabis in extraordinary situations. \u201cA civilized society should not deny access to a medicine to a patient when a doctor says he needs it,\u201d he asserts.<\/p>\n

Accolades for a Swiss Scientist<\/h2>\n

Next up in Basel, Dr. Grotenhermen announces a thank-you award to his friend Dr. Rudolf Brenneisen, the long-term fighter for cannabinoid medicine in the mountainous redoubt of Switzerland. As the founder and chief of the Swiss Task Force for Cannabinoids in Medicine for over ten years, Dr. Brenneisen has advanced the cause of cannabis medicine with his prodigious research and advocacy. More recently, he has criticized the bureaucratic requirements that force a Swiss doctor to apply (and wait for weeks) for a special cannabis permit from the Federal Office of Public Health. Brenneisen prefers the German system that allows patients to buy cannabis from a pharmacy with a prescription.<\/p>\n